Author + information
- Received October 3, 2019
- Revision received November 15, 2019
- Accepted November 17, 2019
- Published online January 27, 2020.
- TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts
- ↵∗Address for correspondence:
Dr. Eugene Braunwald, TIMI Study Group, Brigham and Women’s Hospital, 60 Fenwood Road, 7th Floor, Boston, Massachusetts 02115.
• Patients with T2DM are at high risk of major vascular complications, HF, and chronic kidney disease.
• SGLT2i reduce MACE and progression of chronic kidney disease in patients with T2DM.
• SGLT2i also reduce HF and cardiovascular death in patients with established HF and reduced ejection fraction.
• Ongoing trials are addressing the role of SGLT2i in patients with HF and preserved ejection fraction and chronic kidney disease, with and without T2DM.
Changes in the regulatory guidelines by the U.S. Food and Drug Administration and the European Medical Agency requiring large-scale trials that study the cardiovascular safety of new glucose-lowering drugs have improved our understanding of type 2 diabetes mellitus. Unexpectedly, these trials demonstrated that sodium-glucose cotransporter 2 inhibitors reduce adverse cardiovascular outcomes. This second part of this 2-part review summarizes the findings of recent clinical trials and their clinical implications and describes ongoing trials and future areas of research.
Dr. Zelniker is currently affiliated with the Division of Cardiology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. Dr. Zelniker has received grant support from the German Research Foundation (Deutsche Forschungsgemeinschaft ZE 1109/1-1); and has received lecture fees from AstraZeneca. Dr. Braunwald has received research grants through his institution from AstraZeneca, Daiichi-Sankyo, GlaxoSmithKline, Merck, and Novartis; has consultancies with Amgen, Cardurion, MyoKardia, NovoNordisk, and Verve; has received personal fees for lectures from Medscape; and has performed uncompensated consultancies and lectures with Novartis and The Medicines Company.
- Received October 3, 2019.
- Revision received November 15, 2019.
- Accepted November 17, 2019.
- 2020 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.